1

2 **Amino acid substitutions associated with treatment failure of** 3 **hepatitis C virus infection**

4 María Eugenia Soria^{1,2,3}, Carlos García-Crespo³, Brenda Martínez-González^{1,3}, Lucía
5 Vázquez-Sirvent³, Rebeca Lobo-Vega^{1,3}, Ana Isabel de Ávila³, Isabel Gallego^{3,4}, Qian
6 Chen^{2,4}, Damir García-Cehic^{2,4}, Meritxell Llorens-Revull^{2,4}, Carlos Briones^{4,5}, Jordi
7 Gómez^{4,6}, Cristina Ferrer-Orta⁷, Nuria Verdaguer⁷, Josep Gregori^{2,4,8}, Francisco
8 Rodríguez-Frías^{4,9}, María Buti^{2,4}, Juan Ignacio Esteban^{2,4}, Esteban Domingo^{3,4}, Josep
9 Quer^{2,4} and Celia Perales^{1,2,3,4*}

10

11 ¹*Department of Clinical Microbiology, IIS-Fundación Jiménez Díaz, UAM. Av. Reyes*
12 *Católicos 2, 28040 Madrid, Spain, ²Liver Unit, Internal Medicine Hospital Universitari*
13 *Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), 08035, Barcelona, Spain,*
14 ³*Centro de Biología Molecular “Severo Ochoa” (CSIC-UAM), Consejo Superior de*
15 *Investigaciones Científicas (CSIC), Campus de Cantoblanco, 28049, Madrid, Spain,*
16 ⁴*Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas*
17 *(CIBERehd) del Instituto de Salud Carlos III, 28029, Madrid, Spain, ⁵Centro de*
18 *Astrobiología (CAB, CSIC-INTA), 28850 Torrejón de Ardoz, Madrid, Spain, ⁶Instituto*
19 *de Parasitología y Biomedicina 'López-Neyra' (CSIC), Parque Tecnológico Ciencias de*
20 *la Salud, Armilla, 18016, Granada, Spain, ⁷Structural Biology Department, Institut de*
21 *Biología Molecular de Barcelona CSIC, Barcelona, Spain, ⁸Roche Diagnostics, S.L.,*
22 *Sant Cugat del Vallés, 08174, Barcelona, Spain, ⁹Biochemistry and Microbiology*
23 *Departments, VHIR-HUVH, Barcelona, Spain.*

24

25 *Corresponding author: celia.perales@quironsalud.es; cperales@cbm.csic.es

26

27 Abstract

28 Despite the high virological response rates achieved with current directly-acting
 29 antiviral agents (DAAs) against hepatitis C virus (HCV), around 2% to 5% of treated
 30 patients do not achieve a sustained viral response. Identification of amino acid
 31 substitutions associated with treatment failure requires analytical designs, such as
 32 subtype-specific ultra-deep sequencing (UDS) methods for HCV characterization and
 33 patient management. Using this procedure, we have identified six highly represented
 34 amino acid substitutions (HRSs) in NS5A and NS5B of HCV from 220 patients who
 35 failed therapy, which are not *bona fide* resistance-associated substitutions (RAS). They
 36 were present frequently in basal and post-treatment virus of patients who failed therapy
 37 to different DAA-based therapies. Contrary to several RAS, HRSs belong to the
 38 acceptable subset of substitutions according to the PAM250 replacement matrix.
 39 Coherently, their mutant frequency, measured by the number of deep sequencing reads
 40 within the HCV quasispecies that encode the relevant substitutions, ranged between
 41 90% and 100% in most cases. Also, they have limited predicted disruptive effects on the
 42 three-dimensional structures of the proteins harboring them. Possible mechanisms of
 43 HRS origin and dominance, as well as their potential predictive value of treatment
 44 response are discussed.

45

46 **Keywords:** next-generation sequencing, viral quasispecies, viral fitness, antiviral
 47 agents, viral diagnostics, treatment planning

48

49

50

51

52

53 Introduction

54 Hepatitis C virus (HCV) currently infects chronically around 71 million people
 55 worldwide (<https://www.who.int/news-room/fact-sheets/detail/hepatitis-c>), and it
 56 replicates as mutant clouds called viral quasispecies that confer an enormous adaptive
 57 potential to the virus [1-4]. Despite available direct-acting antiviral (DAA)-based
 58 therapies being extremely effective, in 2% to 5% of treated patients, viral load is not
 59 efficiently suppressed. Given the massive number of patients undergoing treatment
 60 worldwide, characterization of resistance-associated substitutions (RAS) has become
 61 part of HCV therapy management [5-8]. Selection of RAS associated with treatment
 62 failure is increasingly reported, concomitantly with the number of treated patients [9-13].
 63 RAS can be also present in naïve patients who have not received DAA therapies, again
 64 as documented with several cohorts worldwide [14-18].

65 In a recent deep sequencing analysis of 220 subtyped HCV samples from infected
 66 patients who failed therapy, collected from 39 Spanish hospitals, we determined amino
 67 acid sequences of the DAA-target proteins NS3, NS5A and NS5B, by ultra-deep
 68 sequencing (UDS) of HCV patient samples, in search of RAS [9]. Interestingly, 18.6%
 69 of the patients that failed therapy did not include any substitutions that could be
 70 considered *bona fide* RAS, according to current guidelines [6]. Similar observations
 71 have been made with other patient cohorts [10,11,19-26]. This finding has raised the
 72 possibility that mechanisms other than RAS selection may contribute to treatment
 73 failure of HCV-infected patients.

74 Previous model studies with HCV replicating in human hepatoma Huh-7.5 cells
 75 indicated that such alternative mechanisms may exist. Specifically, studies with
 76 isogenic HCV populations (derived from the same initial genome) showed that the virus
 77 endowed with up to 2.3-fold increase in replicative fitness displayed increased
 78 resistance to several classes of anti-HCV inhibitors, including DAAs [27-29].

79 In the present study with HCV of chronically infected patients who failed DAA
 80 therapies, we document that a number of amino acid substitutions in NS5A and NS5B
 81 that are not *bona fide* RAS are present in basal samples (prior to DAA treatment), and
 82 remain dominant in the HCV quasispecies of a considerable proportion of patients.
 83 They have been termed highly represented substitutions (HRS), and can be found in
 84 isolation or in combination in the same viral sample. Their frequency is influenced by
 85 the viral genotype, and contrary to RAS, they belong to the statistically accepted class

of substitutions in protein evolution, and predict minimal distortions in the structure of the corresponding proteins. The recognition of HRS provides new insights into the population dynamics of HCV *in vivo*, suggests that mechanisms other than RAS selection may contribute to treatment breakdown, and opens the possibility that HRS may be used as prognostic markers of DAA treatment response.

Results

Amino acid variations in HCV-infected patients failing DAA-based therapies.

Defining highly represented substitutions (HRSs) in therapy outcome

RAS identified by UDS have been recently described in a cohort of 220 HCV-infected patients failing DAA therapies [9]. To provide a broad picture of all substitutions identified in NS3 (within amino acids 32 to 179), NS5A (within amino acids 24 to 152) and NS5B (within amino acids 124 to 320) proteins in these patients (Table S1), we constructed a heat map representing the frequency of each substitution in each viral sample (Figure 1A). We defined as highly represented those substitutions present in more than 20% of the patients. Contrary to the expectations, only three substitutions (Y93H in NS5A, as well as L159F and C316N in NS5B) out of the nine that fulfilled the frequency criterion belonged to the previously defined RAS [6,30-32] (Figure 1B). The three RAS were not considered part of the HRS for further analyses and calculations in the present study. The percentage of infected patients whose HCV carried any one of the HRS was statistically significant relative to those showing any other amino acid substitution within the protein regions analyzed. According to the proportion test, the range of p values was as follows: for T64A, $p = 3.29 \times 10^{-14}$ to 0.04; for R78K, $p = 1.04 \times 10^{-11}$ to 0.03; for S213C, $p < 2.20 \times 10^{-16}$ to 0.001; for A218S, $p < 2.20 \times 10^{-16}$ to 0.002; for S231N, $p = 4.57 \times 10^{-15}$ to 0.03; for Q309R, $p = 5.57 \times 10^{-12}$ to 0.04. Thus, HRSs stand out over other substitutions by their frequency among patients who failed DAA therapies.

HRS dependence on viral subtype

Since HCV subtype can influence the response to treatment and RAS selection [9,10], it was interesting to explore if HCV subtype may also affect the types of HRSs found in the viral proteins. In NS5A, while T64A was present in patients infected with HCV of

the three main viral genotypes (G1b, G1a and G3a), R78K was found mainly in G1a HCV-infected patients (Figure 2A). For G1a, S213C and A218S were not represented, and the order of the other HRSs according to the percentage of patients harboring them was R78K>Q309R>T64A>S231N. In contrast, for G1b, R78K was not present, and the order of abundance of other HRSs was S213C=A218S>S231N>T64A>Q309R. These differences of distribution among the two genotypes are statistically significant (for T64A, $p=0.03899$ and $p=5.89 \times 10^{-4}$ for the comparison between G1b and G1a or G3a, respectively; for R78K, S213C and A218S, $p=2.2 \times 10^{-16}$ for the comparisons between G1a and G1b; for S231N and Q309R, $p=3.4 \times 10^{-14}$ and $p=5.9 \times 10^{-6}$ for the comparisons between G1a and G1b, respectively; proportion test). These results suggest that the HRSs display a certain degree of subtype specificity, as has been previously reported for RAS [6,9,10].

130

131 **Frequency of individual and combined HRSs in HCV quasispecies and among** 132 **HCV-infected patients**

The frequency of HRSs within the HCV mutant spectra of individual HCV samples was calculated from the percentage of UDS reads carrying each relevant mutation, taking into consideration the 1% limit of detection of amino acid substitutions [33]. Ninety-four percent of HRSs were found at frequencies that ranged between 90% and 100% in the viral quasispecies, whereas only 6% of them were found at frequencies between 1% and 89.9% ($p < 2.2 \times 10^{-16}$; proportion test) (Figure S1). Therefore, a high representation among patients paralleled a high frequency in the HCV mutant spectrum of each patient.

To study whether HRSs at NS5A and NS5B occur independently or they are preferentially combined in individual infected patients, the percentage of patients carrying HCV genomes with single, double, triple, quadruple and quintuple combinations was compared with the frequency expected from their individual frequency among patients (Figure 2B and Table S2). Application of Bayes theorem indicated that for genotype G1a there were no significant differences between observed and expected HRS associations ($p=0.0589$; chi-square test with Monte Carlo correction). For the most represented HRS combinations, the p values calculated with the proportion test were $p=0.1732$ for the R78K+Q309R, and $p=0.2089$ for T64A+R78K+Q309R. For HCV G1b no difference was evidenced by application of Bayes theorem ($p=1.00$; chi-square test with Monte Carlo correction). For the most

152 represented combinations, the proportion test yielded $p=0.2334$ for the combination
153 S213C+A218S, $p=0.0551$ for S213C+A218S+S231N and $p=0.1047$ for
154 T64A+S213C+A218S+S231N. Thus, in the majority of cases the frequency of
155 associated HRS is that expected from their individual or combined frequencies in
156 infected patients.

157

158 **Prevalence of HRS in basal (prior to treatment) samples**

159 To further investigate the possible origin of the HRSs found after treatment
160 failure, we analyzed whether HRSs were already present before treatment
161 implementation. To this aim, we had available 69 paired basal-failure samples that were
162 analyzed following the same UDS procedure [9,33]. Seventy-four percent of the paired
163 basal-failure samples carried at least one of the HRSs in the basal and/or post-treatment
164 sample. For HCV G1a and G1b separately, a distinction was made for each HRS to
165 indicate if its frequency within the viral quasispecies was equal or different between the
166 basal and the post-treatment sample (Figure 3A and Table S3). The frequency of most
167 HRSs was similar in the two paired samples. The results suggest that at least part of the
168 HRSs found following treatment failure are dictated by their presence prior to treatment.
169 Regarding the percentage of patients, the conclusion is also valid for HRS combinations
170 found in basal and post-treatment samples (Figure 3B). A large proportion (62.5%) of
171 double or higher order HRS combinations were present both in the basal and post-
172 treatment HCV sample. Thus, the difference in HRSs and their combinations between
173 the basal and the post-treatment sample was not statistically significant for patients
174 infected with HCV G1a ($p=0.5417$; chi-square test with Monte Carlo correction), and
175 virtually inexistent for those infected with HCV G1b ($p=0.9925$; chi-square test with
176 Monte Carlo correction).

177 A distribution of individual HRS among the twelve different DAA-based
178 treatments undergone by the patients confirmed both the prevalence of HRS prior to the
179 therapy and their maintenance (in most cases) following treatment, both regarding the
180 percentage of patients with a given HRS, and the frequency of each HRS in the patient
181 quasispecies (Figure 4). Therefore, HRSs at treatment failure are largely determined by
182 their presence prior to DAA treatment.

183

184 **Association of HRS with RAS**

To evaluate the possible association between HRS and RAS in our cohort, we quantified the number of patients whose HCV contained both substitution categories in the virus sample obtained after treatment failure (Figure S2). In most cases there is a statistically significant association of HRSs and RASs in HCV from patients who failed therapy: 90% of patients were infected with HCV harboring at least one HRS combined with RAS whereas only 10% carried at least one HRS without RAS ($p = 2.2 \times 10^{-16}$; proportion test). Interestingly, combinations of the RAS L159F or C316N with the HRSs S213C or A218S are statistically significant as compared to combinations with other HRSs such as T64A, R78K, S231N and Q309R (Table S4). Also, combinations of the HRSs S213C+A218S and S213C+A218S+S231N were mainly associated with RAS L159F and C316N. Specifically, in all patients whose HCV contains RAS C316N, HRS A218S was also found.

Tolerance of the substitution repertoire at treatment failure

To investigate possible differences between the amino acids that conform the HRS criterion, those involved in RAS, and other substitutions found at lower frequency in the same cohort following treatment failure, the acceptability of each substitution was quantified according to the PAM250 matrix (Figure S3). This value provides three levels of substitution acceptability based on amino acid structural resemblance and genetic inter-convertibility (PAM250<0, lower acceptability than expected, meaning a rare replacement; PAM250=0, acceptability as expected; PAM250>0 acceptability higher than expected) [34]. More than fifty percent ($59 \pm 4.7\%$) of the total number of amino acid substitutions (HRS, RAS, and others) found at treatment failure display a PAM250 value higher than 0, indicating a high average acceptability of amino acid substitutions (Figure S3A). The most salient difference is that 19.3% of all substitutions belong to PAM250<0 while for RAS the proportion increases to 38.5% for the NS5B region (Figure S3A and S3B). In contrast, all HRS correspond to PAM250 ≥ 0 (Figure S3C).

To evaluate if a PAM250 acceptance category was associated with the percentage of patients harboring an amino acid substitution in each category, the frequency of patients in which any amino acid substitution occurred was divided in six categories: >20%, 15%-19.9%, 10%-14.9%, 5%-9.9%, 1%-4.9%, and 0.5%-0.9%. The amino acid substitutions in NS3, NS5A and NS5B that belong to a PAM250 category were

distributed among the patient frequency groups (Figure S3D). The less accepted substitutions (those with PAM250<0) were mainly found in the low frequency groups of patients, with a difference that was statistically significant relative to the higher patient frequency groups (Table S5). These associations are expected from the fact that replacements that are not well tolerated tend to inflict a larger fitness cost upon the virus, thus attaining lower frequency among patients than those with high acceptance. Of note, the HRSs characterized in our study belong to well tolerated class of amino acid substitutions.

Substitution tolerance and its relationship with residue conservation in data banks

We have recently described that amino acid conservation in the Los Alamos HCV databank (LANL) (<https://hcv.lanl.gov/content/sequence/HCV/ToolsOutline.html>) did not match low amino acid substitution frequency in HCV mutant spectra quantified both in cell culture and in HCV-infected patients [35]. In view of this unexpected result, it was interesting to determine the relationship between PAM250 values and the conservation range of amino acid positions according to the LANL alignment. The number of substitutions belonging to a defined PAM250 category and the total number of substitutions (comprising all PAM250 categories) was plotted as a function the degree of conservation of the amino acid at each position, calculated relative to the most abundant residue in the corresponding position of the LANL alignment (Figure 5 A-D). In all cases, the distribution followed a pattern which is very similar to that previously described for several HCV quasispecies at the nucleotide and amino acid level [35]. Only minor differences were noted in the distribution calculated for different PAM250 categories, and they did not reach statistical significance ($p=0.7865$, chi-square test with Monte Carlo correction).

The distribution pattern was also very similar when both HRS and RAS were excluded (Figure 5E). In contrast, the distribution of the 141 RAS substitutions differed in that 32.6% of the substitutions fell into the 40%-50% conservation category ($p = 2.77 \times 10^{-14}$; proportion test) (Figure 5F). The HRSs were spread among intermediate conservation categories (Figure 5G). A similar distribution was found when the cut-off level of percentage of patients with non-RAS substitutions was relaxed to 10% (Figure 5G). The previously described distribution of quasispecies mutations and amino acid substitutions among the LANL conservation groups denotes a higher tolerability of

251 mutations at the quasispecies level than reflected in the consensus sequences that
252 compose the LANL databank [35]. This implies that the HRSs described in our study are
253 not constrained by a limitation of acceptability or by belonging to the most conserved
254 amino acids according to the LANL.

255 Forty, twenty-four, and twenty positions in NS3-, NS5A- and NS5B-coding regions
256 remained invariant, and were spread among the most conserved categories (80%-100%)
257 (Figure 5H).

258

259 **Localization of HRS in the NS5A and NS5B structure**

260 The three-dimensional structures of NS5A and NS5B proteins of HCV genotype
261 1b were used to localize the RAS and HRS positions [Protein Data Bank
262 (<http://www.wwpdb.org/>), accession numbers 1ZH1 and 5TRH for NS5A and NS5B,
263 respectively] (Figure 6). In NS5A, the HRS positions 64 and 78 are located at the
264 protein surface with side chains totally exposed to the solvent. Substitutions T64A and
265 R78K can be easily accommodated without causing major distortions in structure
266 (Figure 6A). Substitutions in position 93 represent one of the major antiviral resistance
267 changes in HCV genotypes 1a and 1b [36]. As shown in Figure 6A, the NS5A position
268 93 can accommodate both Tyr and His side chains, maintaining similar neighboring
269 interactions.

270 Similar to that observed in the NS5A structure, the amino acid positions 213,
271 231 and 309 in the NS5B polymerase, including most of HRS positions, are also solvent
272 exposed at the protein surface, and replacements S213C, S231N and Q309R can be
273 easily accommodated in the structure without distortions. Residues 213 and 309 are
274 located at the base of the palm subdomain and amino acid 231 is in an exposed position
275 in the polymerase fingers (Figure 6B). The calculated distances between these amino
276 acid positions and the active site are 26.5 Å, 22 Å and 17.2 Å, respectively, for amino
277 acids C213, R309 and N231. Considering that these three residues are far from the
278 active site, it is not expected that such substitutions could affect the activity of the
279 polymerase.

280 The HRS A218S is located in the palm subdomain, within the β -strand that
281 conforms motif A (Figure 6B), and exposed on the surface of the NTP tunnel. It is also
282 in close proximity to the catalytic Asp residues (at 6.5 Å distance of D220 in motif A
283 and at 11 Å of D318 of motif C). S218 is also close to the RAS mutation N316 (11.4

284 Å). However, neither the A218S nor C316N substitutions appear to distort the structure
285 of polymerase catalytic site. The potential impact of the C316N mutation on efficacy of
286 the antiviral drug sofosbuvir in patients infected with HCV genotype1b has been
287 previously evaluated. The authors suggested that the bulkier N316 side chain would
288 partially block the access of the nucleotide analog to the polymerase active site by
289 inducing steric hindrance with the additional 2'Me and 2'F groups of sofosbuvir
290 compared to natural nucleotides [37].

291 Finally, RAS L159F is located in the fingers motif F, forming part of the
292 template channel (Figure 6B). However, its side chain is not oriented towards the
293 channel but packed towards the polymerase interior, participating in hydrophobic
294 cluster. The replacement of L159 by the bulkier F side chain would add new
295 interactions to the cluster, though causing only minimal distortions (Figure 6B).

296 **A comparison of HRS frequency between a cohort of HCV-patients with treatment** 297 **failure and a cohort with sustained viral response**

298 To investigate if HRSs might have predictive value regarding DAA-based treatment
299 outcome, we compared the presence of each HRS in the basal samples of our cohort [9]
300 whose outcome was treatment failure, and in basal samples of another cohort [38] whose
301 outcome was sustained virological response (SVR). The results (Figure 7) indicate
302 statistically significant differences in the percentage of patients who carried some (but
303 not all) HRSs (Table S6). The most striking difference was the absence of T64A in
304 HCV genotype G1a in those patients who achieved SVR. The observed differences
305 open the possibility that some HRSs may assist in predicting treatment response, a
306 suggestion that must await identification of additional HRSs in other cohorts.

307

308 **Discussion**

309 HCV replicating in infected patients displays the complex quasispecies dynamics
310 expected from low-fidelity replication in any environment, independently of external
311 perturbations [39,40]. New mutations arise and vary in frequency as a function of time,
312 due to selective forces and random sampling events. Only a subset of all mutations
313 become dominant in response to antiviral agents. Such a subset conforms the list of
314 RAS that, in the case of HCV, is periodically updated with the aims of interpreting
315 antiviral intervention failures and to aid in treatment planning [6]. However, and
316 important, not all amino acid substitutions that vary in frequency during intra-host HCV

317 evolution, and that increase their frequency in the quasispecies, need be the result of
318 direct selection by antiviral agents. Several reports have described amino acid
319 substitutions in cohorts of treated and untreated HCV-infected patients that are not *bona*
320 *fide* RAS, and whose contribution to treatment failures is uncertain [37,41-44].

321 We have examined this open question with a large cohort of 220 HCV-infected
322 patients that failed DAA-based therapies, since 25 patients did not exhibit any known
323 RAS after treatment failure [9]. Using UDS information of the 220 HCV-infected
324 patients, we have characterized a new class of amino acid substitutions that we have
325 termed HRS. We examined the proportion of patients in whom they are present, their
326 frequency within the mutant spectrum of the quasispecies, and their statistical
327 acceptability based on parameters employed in studies of protein evolution. An HRS
328 differs from a RAS in the following features: (i) they are not listed as RAS in current
329 RAS catalogues [6,31,32]; (ii) they can be found in basal samples and remain dominant
330 in patients undergoing different DAA treatments; (iii) they correspond to well accepted
331 substitutions according to the PAM250 replacement matrix, and (iv) they belong to
332 intermediate conservation categories according to the conservation range of amino acid
333 positions in the LANL alignment.

334 Some of the HRSs identified in our cohort are dominant for a specific HCV subtype
335 but not for others (i.e. in position 78 in NS5A, the wt (reference) amino acid is a R for
336 G1a but K for G1b; in position 218 in NS5B, the wt (reference) amino acid is S for G1a
337 but A for G1b) [also found in [37,38]]. Additionally, while HRS combinations in basal
338 samples amounted to 62.5% of patients infected with HCV G1a, they represented only
339 12.5 % for infections with G1b. These differences argue in favor of an influence of the
340 HCV genetic background in HRS occurrence and prominence. HRS acceptability is also
341 consistent with the limited perturbations predicted to inflict on the proteins harboring
342 them, according to modeling of the effect of the relevant substitutions on the three-
343 dimensional structure of the proteins. The fact that 34.5% of patients carrying one or
344 more HRSs were neither treated nor failed to drugs whose target are the proteins where
345 the HRSs were located, reinforces the lack of association between HRS presence and a
346 specific treatment.

347 Some of the HRS that we have characterized, have been also reported in other
348 cohorts, with no evidence of them being RAS. Uchida *et al.* identified A218S+C316N
349 in the G1b viral population that became dominant upon failure to LDV+SOF, as well as
350 in SOF-naïve patients [37]. We have also identified A218S in patients never subjected to

351 SOF treatment, despite evidence that this substitution may jeopardize the access of
352 SOF-triphosphate to the catalytic site of NS5B [37]. Bellocchi *et al.* (2019) identified
353 K78R and T64A in NS5A and C213S, S231N, N231S and A218S in HCV G1b-infected
354 patients naïve to DAAs [43]. T64S in NS5A was listed as a secondary substitution
355 accompanying P58S and Y93H in HCV G1b-infected patients who failed DCV therapy,
356 with a resistance level of $EC_{50} < 1$ nmol/l [44].

357 The observations regarding Q309R are worth commenting. While this substitution
358 has been previously associated with ribavirin (RIB) resistance [45,46], a direct specific
359 involvement in RIB resistance is not obvious. For HCV G1b-infected patients, Kim *et al.*
360 found Q309R at high frequency in the quasispecies of treatment-naïve patients [42],
361 and Jiang *et al.* described it at lower frequency in G1b-infected patients, prior to
362 treatment [47]. In our cohort, Q309R was present in the basal samples of several
363 patients. Although we cannot exclude that some patients had undergone a prior pegIFN-
364 α +RIB treatment, or that they were infected with virus from patients that had undergone
365 RIB-containing therapies, the frequency of genomes with Q309R remained high during
366 DAA therapy, independently of their including RIB.

367 Discrepancies between clinical observations and results of the effect of mutations
368 using replicon systems [37], added to the multiple genetic backgrounds in which a
369 specific amino acid substitution (alone or in combination) should be tested *in vitro*,
370 renders very difficult a definitive assignment of a substitution to the HRS category and
371 its total exclusion from any RAS activity.

372 The possible origin of HRS as a result of some selective constraint that acted during
373 the prior evolutionary history of the virus cannot be excluded, but identification of the
374 potential selective agent is challenging. For example, none of the HRS we have
375 characterized maps within conserved T cell epitopes predicted in NS5A and NS5B by
376 bioinformatic procedures [48], suggesting that the origin of HRS is unrelated to escape
377 from cellular immune responses. Probably, we have identified only a minimum subset
378 of the constraints to which viruses are subjected in their natural environments. One
379 possibility is that HRS may be prompted by their favoring viral fitness irrespectively of
380 being or not together with a RAS in the same genome. Fitness has multiple survival-
381 enhancing effects on evolving viral populations [49]. A possible survival value of HRS
382 should be more noticeable in the presence of those RAS that inflict a fitness cost.
383 Moreover, using HCV infection of human hepatoma cells in culture, we have
384 documented that fitness *per se* (in absence of any RAS, ascertained by different

procedures) is a determinant of HCV multidrug resistance, including IFN- α , DAAs, cyclosporine A (that targets a cellular protein), and the mutagenic analogues favipiravir and RIB [27-29]. In view of these results, it is tempting to consider that the HRS class of substitutions may play a fitness-enhancing role. They would be the counterpart in infected patients of the multiple mutations scattered along the HCV genome that have been associated with fitness increase of HCV in cell culture [50].

Regarding the diagnostic relevance of HRS, if our findings are confirmed with additional patient cohorts, a baseline identification of HRS may provide information to be added to other predictors of treatment outcome, be them RAS presence, or quasispecies complexity [51]. As an example, Mawatari et al. observed that in a cohort of G1b-infected patients, when A218S and C316N were absent, SVR was achieved in all cases [41]. Sequencing of basal samples is a recommendation for treatment planning. Therefore, the information on HRS that will be gathered during sequencing should be relevant not only to help predicting treatment outcomes, but also to further understand HCV population dynamics which appears much more complex than thought prior to introduction of deep sequencing.

401

402 **Materials and Methods**

403 Experimental data on HCV-infected patients. DNA amplifications from viral RNA
404 was performed using subtype-specific oligonucleotides previously described.
405 Amplification and PCR-mediated recombination errors, and reproducibility the same or
406 different sequencing platforms were controlled experimentally and bioinformatically
407 [33,52]. Deep sequencing procedures, patient clinical data and HCV sequences from
408 infected patients have been previously described [9]. The cut-off frequency of amino
409 acid substitution detection was 1% [33]. Similar procedures were used for the
410 amplification and sequencing of pre-treatment (basal) and post-treatment samples.

411

412 Sequences from the Los Alamos data base. The sequences were retrieved from LANL
413 following previously described procedures [33]. Inclusion criteria were that the
414 sequences had been confirmed, with no evidence of their being recombinants, and that
415 they corresponded to full-length (or near-full length) genomes (without large insertions
416 or deletions). Their HCV genotype / subtype distribution is: 553 sequences of genotype
417 G1a; 427 of G1b; 3 of G1c; 33 of G2a; 81 of G2b; 7 of G2c; 5 of G2j; 3 of G2k,

although no distinction between HCV subtypes was made for the calculation of the conservation range of individual residues. Alignments were performed using the program BioEdit version 7.0.9.0.

Statistics. The statistical significance of differences in the distribution of variable sites among conservation groups was calculated with the Pearson's chi-square test using software R version 3.6.2, with Monte Carlo correction (based on 2000 replicates). Sample sizes are given for each comparison. The proportion test using software R version 3.6.2 was used for multiple determinations.

Sequence accession numbers and data availability. The reference accession numbers of sequences retrieved from LANL used to determine conservation groups are given in [35]. Accession numbers for HCV samples included in the patient cohort are SAMN08741670 to SAMN08741673 [33]. Amino acid replacements in HCV from infected patients have been compiled in Table S1.

Acknowledgments

The work at CBMSO was supported by grants SAF2014-52400-R from Ministerio de Economía y Competitividad (MINECO), SAF2017-87846-R, BFU2017-91384-EXP from Ministerio de Ciencia, Innovación y Universidades (MICIU), PI18/00210 from Instituto de Salud Carlos III, S2013/ABI-2906, (PLATESA from Comunidad de Madrid/FEDER) and S2018/BAA-4370 (PLATESA2 from Comunidad de Madrid/FEDER). C.P. is supported by the Miguel Servet program of the Instituto de Salud Carlos III (CP14/00121 and CPII19/00001) cofinanced by the European Regional Development Fund (ERDF). CIBERehd (Centro de Investigación en Red de Enfermedades Hepáticas y Digestivas) is funded by Instituto de Salud Carlos III. Institutional grants from the Fundación Ramón Areces and Banco Santander to the CBMSO are also acknowledged. The team at CBMSO belongs to the Global Virus Network (GVN). The work in Barcelona was supported by Instituto de Salud Carlos III, cofinanced by the European Regional Development Fund (ERDF) grant number PI19/00301 and by the Centro para el Desarrollo Tecnológico Industrial (CDTI) from the MICIU, grant number IDI-20151125. Work at CAB was supported by MINECO grant BIO2016-79618R and PID2019-104903RB-I00 (funded by EU under the FEDER program) and by the Spanish State research agency (AEI) through Project number

MDM-2017-0737 (Unidad de Excelencia “María de Maeztu”-Centro de Astrobiología (CSIC-INTA). Work at IBMB was supported by MICIN grant BIO2017-83906-P (funded by EU under the FEDER program). C. G.-C. is supported by predoctoral contract PRE2018-083422 from MICIU. B. M.-G. is supported by predoctoral contract PFIS FI19/00119 from Instituto de Salud Carlos III (Ministerio de Sanidad y Consumo) cofinanced by Fondo Social Europeo (FSE).

Figure legends

Figure 1. Heat map of amino acid substitutions and their distribution among patients, following treatment failure with DAAs. (A) The amino acid residues that were sequenced within proteins NS3, NS5A, and NS5B are indicated at the top. In parenthesis the protein length of NS3, NS5A and NS5B is indicated. Each horizontal dot alignment represents one of the total 220 patients analyzed (ordinate). Each vertical dot alignment corresponds to an amino acid position where an amino acid substitution was found; the substitution frequency in a sample (given by the proportion of reads with the relevant amino acid substitution) is denoted by the dot color: black (90.1-100%), grey (80.1-90%), pink (70.1-80%), purple (60.1-70%), red (50.1-60%), green (40.1-50%), orange (30.1-40%), yellow (20.1-30%), brown (10.1-20%), blue (1-10%) and white (<1%, below the limit of detection). The excel file including all amino acid frequencies represented by colors is available upon request. (B) Distribution of the amino acid substitutions depicted in A, according to the percentage of patients in whom each substitution was found (ordinate). The discontinuous horizontal line marks the 20% cut-off patient frequency used to define prevalent substitutions. The highly represented substitutions (HRSs) are indicated with a black triangle, and *bona fide* resistance-associated substitutions (RAS) with a red triangle, below the boxes. The complete list, location, statistical acceptability, and frequency among patients of all amino acid substitutions is given in Table S1.

Figure 2. Distribution of single and combined HRSs among subtypes, following treatment failure with DAAs. (A) The circle on the left indicates the percentage of patients carrying at least one HRS. On the right the HRS distribution according to viral protein and HCV subtype is represented. The number in parenthesis indicates the percentage of patients carrying each HRS considering the 220 patient cohort. (B)

483 Distribution of single and combined HRSs in the failure (post-treatment) samples. The
 484 display is divided into data for HCV genotype G1a (top bloc) and G1b (bottom bloc).
 485 For each bloc, the top panel indicates the percentage of patients (ordinate) in whom
 486 single or combined HRSs is found (individual or linked black circles below the panel).
 487 At the left of the HRS list, the grey horizontal bars depict the percentage of patients of
 488 each subtype (G1a and G1b) in whom each HRS is found; absence of a bar means that
 489 the HRS was absent. The protein where each HRS maps is shown on the right. It should
 490 be noted that the HRS associations are based on their presence in the same HCV
 491 sample, deduced from the same or different amplicons. Linkage of two HRSs in the
 492 same genomic molecule can be only indirectly inferred from their abundance in their
 493 corresponding amplicon population. Cases in which differences are statistically
 494 significant are indicated: ns=not significant; * $p<0.05$; ** $p<0.01$; *** $p<0.001$;
 495 proportion test. P values are indicated in the supplementary Table S2.

496

497 **Figure 3. Comparison of the frequency of individual and combined HRSs in HCV**
 498 **from patients in the basal (pre-treatment) and post-treatment (failure) samples.**

499 **(A)** Distribution of the individual HRSs (given in abscissa) among patients (ordinate),
 500 according to their frequency in the post-treatment sample being equal (in all cases
 501 between 90%-100% within the viral quasispecies), higher or lower than in the pre-
 502 treatment sample (vertical bars with code in upper box). Cases in which differences are
 503 statistically significant are indicated: * $p<0.05$; ** $p<0.01$; *** $p<0.001$; proportion test.
 504 P values are indicated in the supplementary Table S3. **(B)** Distribution of single and
 505 combined HRSs in the basal (pre-treatment) and failure (post-treatment) samples (code
 506 in box on the right). The display is divided into data for HCV genotype G1a (top bloc)
 507 and G1b (bottom bloc). For each bloc, the top panel indicates the percentage of patients
 508 (ordinate) in whom single or combined HRSs is found (individual or linked black
 509 circles below the panel). At the left of the HRS list, the grey horizontal bars depict the
 510 percentage of patients of each subtype (G1a and G1b) in whom each HRS is found;
 511 absence of a bar means that the HRS was absent. The protein where each HRS maps is
 512 shown on the right. The HRS associations are based on their presence in the same HCV
 513 sample, deduced from the same or different amplicons; limitations for conclusions on
 514 HRS linkage in the same genome explained in the legend for Figure 2 apply also here.

515

Figure 4. Comparison of individual HRSs in HCV in the basal (pre-treatment) and failure (post-treatment) samples according to the treatment. Frequency of each HRS in the viral quasispecies in the basal (pre-treatment) and failure (post-treatment) samples. For each HRS (given inside each panel) and treatment (top box), the frequency value for pre and post samples (arrows with color code in the top box) were calculated as an average of the values for the patients that underwent the indicated treatment. Drug abbreviations: LDV: ledipasvir; SOF: sofosbuvir; RIB: ribavirin; PTV/r: paritaprevir/ritonavir; OMV: ombitasvir; DSV: dasabuvir; SMV: simeprevir; DCV: daclatasvir; GLE: glecaprevir; PIB: pibrentasvir; IFN: interferon.

Figure 5. Number of amino acid substitutions in HCV from patients who failed therapy, distributed among conservation groups according to the LANL alignment. (A) Number of substitutions with PAM250>0 distributed among conservation groups, calculated relative to the most abundant amino acid at the corresponding position in the LANL alignment. Conservation groups are indicated in abscissa, and the number of substitutions in each group is given in ordinate (grey bars). The percentage of amino acid substitutions belonging to each category is indicated above each bar. The discontinuous line corresponds to function $y = -112.8\ln(x) + 241.16$ ($R^2 = 0.8045$). (B) Same as A but with amino acid substitutions with PAM250=0. The discontinuous line corresponds to function $y = -46.22\ln(x) + 96.506$ ($R^2 = 0.8452$). (C) Same as A but with substitutions with PAM250<0. The discontinuous line corresponds to function $y = -37.85\ln(x) + 81.366$ ($R^2 = 0.6868$). (D) Same as A but with the total number of amino acid substitutions. The discontinuous line corresponds to function $y = -196.8\ln(x) + 419.03$ ($R^2 = 0.8035$). (E) Number of amino acid substitutions, excluding HRSs and RASs, distributed among conservation groups, calculated relative to the most abundant amino acid at the corresponding position in the LANL alignment. The discontinuous line corresponds to function $y = -182.9\ln(x) + 383.26$ ($R^2 = 0.8096$). (F) Same as E but with RAS. The discontinuous line corresponds to function $y = -13.81\ln(x) + 34.955$ ($R^2 = 0.366$). (G) Same as E but with HRSs (present in more than 20% of patients), and relaxed HRSs (present in more than 10% of patients). The grey line corresponds to function $y = -0.0606x^2 + 0.5697x - 0.2$ ($R^2 = 0.4242$) for HRSs, and the discontinuous line corresponds to function $y = -0.1742x^2 + 1.4379x + 1.5$ ($R^2 = 0.6459$) for relaxed HRSs. (H) Same as E but with invariant

positions in NS3, NS5A and NS5B. The black line corresponds to function $y = 0.8636x^2 - 11.645x + 34.8$ ($R^2 = 0.6351$) for NS3; the discontinuous line corresponds to the function $y = 0.5152x^2 - 6.9515x + 20.8$ ($R^2 = 0.642$) for NS5A; and the grey line corresponds to the function $y = 0.4545x^2 - 6.0909x + 18$ ($R^2 = 0.5758$) for NS5B. The complete list, location, statistical acceptability, and frequency among patients of all amino acid substitutions is given in Table S1.

Figure 6. Positioning of amino acid substitutions, in NS5A and NS5B proteins, associated with treatment failure in HCV infection. (A) Cartoon representation of the NS5A protein structure (light blue) from HCV genotype 1b (PDB id 1ZH1), where the HRS T64A, R78K and RAS Y93H substitutions have been depicted as spheres (left panel). The right panel shows a close up view of the H93 substitution with surrounding residues in a 5 Å radius. (B) Cartoon representation of the HCV NS5B (RdRP) (genotype 1b; PDB id 5TRH) with the conserved structural motifs highlighted in different colors (A, red; B, green; C, yellow; D, sand; E, cyan; F, blue; G, pink). The side chains of residues with RAS (L159F, C316N) and HRS (S213C, A218S, S231N, Q309R) substitutions have been shown as spheres and labelled (central panel). Close up views of the substituted amino acids (ball and sticks and bold labels) with neighboring residues, in a 5 Å radius. The RAS substitution F159 is located within motif F of NS5B in close contact with a cluster of hydrophobic and aromatic residues (upper left panel). The RAS substitution N316 (top right panel) is in palm motif C, in a position previous to the catalytic site (G317D318D319). In contrast, HRS substitutions are located in highly exposed regions: in the fingers domain, N231(bottom left panel), at the base of the palm, C213 and R309 (bottom center panel), and in the β-strand that conforms the palm motif A, S218 (bottom right panel).

Figure 7. A comparison of HRS occurrence in basal samples of our cohort and in a cohort of patients who achieved sustained virological response. The presence of an HRS (indicated in each panel) was examined in the 50 basal (prior to treatment) samples of our patient cohort (8) whose outcome was treatment failure (black bars), and 112 basal samples from another patient cohort (34) whose outcome was sustained virological response (SVR) (grey bars). The HCV genotype is given in abscissa, and the percentage of patients carrying a HRS is written in ordinate. The statistical significance

of the difference in the frequency of HRS between the two cohorts is indicated (ns=not significant; * $p<0.05$; ** $p<0.01$; *** $p<0.001$; proportion test). #means that the HRS R78K in NS5A and A218S in NS5B cannot be considered because the reference amino acid for G1b is a K and for G1a an S, respectively.

References

1. Andino, R.; Domingo, E. Viral quasispecies. *Virology* **2015**, 479-480, 46-51, doi:10.1016/j.virol.2015.03.022.
2. Domingo, E.; Sheldon, J.; Perales, C. Viral quasispecies evolution. *Microbiol Mol Biol Rev* **2012**, 76, 159-216.
3. Schuster, P. Quasispecies on fitness landscapes. In: E. Domingo and P. Schuster, eds. Quasispecies: From Theory to Experimental Systems. In *Curr Top Microbiol Immunol*. 392: 61-120, 2016.
4. Domingo, E.; Perales, C. Quasispecies and virus. *European biophysics journal : EBJ* **2018**, 47, 443-457, doi:10.1007/s00249-018-1282-6.
5. Bradshaw, D.; Mbisa, J.L.; Geretti, A.M.; Healy, B.J.; Cooke, G.S.; Foster, G.R.; Thomson, E.C.; McLauchlan, J.; Agarwal, K.; Sabin, C., et al. Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group. *J Infect* **2019**, 79, 503-512, doi:10.1016/j.jinf.2019.10.007.
6. European Association for the Study of the Liver. Electronic address, e.e.e.; European Association for the Study of the, L. EASL Recommendations on Treatment of Hepatitis C 2018. *J Hepatol* **2018**, 69, 461-511, doi:10.1016/j.jhep.2018.03.026.
7. Kalaghatgi, P.; Sikorski, A.M.; Knops, E.; Rupp, D.; Sierra, S.; Heger, E.; Neumann-Fraune, M.; Beggel, B.; Walker, A.; Timm, J., et al. Geno2pheno[HCV] - A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents. *PLoS One* **2016**, 11, e0155869, doi:10.1371/journal.pone.0155869.
8. Pawlotsky, J.M. DAA failures in African patients with "unusual" HCV subtypes: Hey! Didn't you know there was another world? *J Hepatol* **2019**, 71, 1070-1072, doi:10.1016/j.jhep.2019.09.021.
9. Chen, Q.; Perales, C.; Soria, M.E.; Garcia-Cehic, D.; Gregori, J.; Rodriguez-Frias, F.; Buti, M.; Crespo, J.; Calleja, J.L.; Tabernero, D., et al. Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. *Antiviral Res* **2019**, 174, 104694, doi:10.1016/j.antiviral.2019.104694.
10. Di Maio, V.C.; Cento, V.; Lenci, I.; Araghi, M.; Rossi, P.; Barbaliscia, S.; Melis, M.; Verucchi, G.; Magni, C.F.; Teti, E., et al. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. *Liver Int* **2017**, 37, 514-528, doi:10.1111/liv.13327.
11. Dietz, J.; Susser, S.; Vermehren, J.; Peiffer, K.H.; Grammatikos, G.; Berger, A.; Ferenci, P.; Buti, M.; Mullhaupt, B.; Hunyady, B., et al. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals. *Gastroenterology* **2018**, 154, 976-988 e974, doi:10.1053/j.gastro.2017.11.007.
12. Perpinan, E.; Caro-Perez, N.; Garcia-Gonzalez, N.; Gregori, J.; Gonzalez, P.; Bartres, C.; Soria, M.E.; Perales, C.; Lens, S.; Marino, Z., et al. Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals. *J Viral Hepat* **2018**, 10.1111/jvh.12986, doi:10.1111/jvh.12986.
13. Sorbo, M.C.; Cento, V.; Di Maio, V.C.; Howe, A.Y.M.; Garcia, F.; Perno, C.F.; Ceccherini-Silberstein, F. Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. *Drug resistance updates : reviews and*

- commentaries in antimicrobial and anticancer chemotherapy **2018**, 37, 17-39, doi:10.1016/j.drug.2018.01.004.
14. Costantino, A.; Spada, E.; Equestre, M.; Bruni, R.; Tritarelli, E.; Coppola, N.; Sagnelli, C.; Sagnelli, E.; Ciccaglione, A.R. Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C. *Virol J* **2015**, 12, 186, doi:10.1186/s12985-015-0414-1.
15. Esposito, I.; Marciano, S.; Haddad, L.; Galdame, O.; Franco, A.; Gadano, A.; Flichman, D.; Trinks, J. Prevalence and Factors Related to Natural Resistance-Associated Substitutions to Direct-Acting Antivirals in Patients with Genotype 1 Hepatitis C Virus Infection. *Viruses* **2018**, 11, doi:10.3390/v11010003.
16. Li, Z.; Chen, Z.W.; Li, H.; Ren, H.; Hu, P. Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China. *Infect Drug Resist* **2017**, 10, 377-392, doi:10.2147/IDR.S146595.
17. Li, Z.; Liu, Y.; Zhang, Y.; Shao, X.; Luo, Q.; Guo, X.; Lin, G.; Cai, Q.; Zhao, Z.; Chong, Y. Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naïve HCV Genotype 6a-Infected Patients. *BioMed research international* **2017**, 2017, 9849823, doi:10.1155/2017/9849823.
18. Yang, S.; Xing, H.; Feng, S.; Ju, W.; Liu, S.; Wang, X.; Ou, W.; Cheng, J.; Pan, C.Q. Prevalence of NS5B resistance-associated variants in treatment-naïve Asian patients with chronic hepatitis C. *Arch Virol* **2018**, 163, 467-473, doi:10.1007/s00705-017-3640-6.
19. Foster, G.R.; Pianko, S.; Brown, A.; Forton, D.; Nahass, R.G.; George, J.; Barnes, E.; Brainard, D.M.; Massetto, B.; Lin, M., et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. *Gastroenterology* **2015**, 149, 1462-1470, doi:10.1053/j.gastro.2015.07.043.
20. Jacobson, I.M.; Gordon, S.C.; Kowdley, K.V.; Yoshida, E.M.; Rodriguez-Torres, M.; Sulkowski, M.S.; Shiffman, M.L.; Lawitz, E.; Everson, G.; Bennett, M., et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. *N Engl J Med* **2013**, 368, 1867-1877, doi:10.1056/NEJMoa1214854.
21. Lawitz, E.; Lalezari, J.P.; Hassanein, T.; Kowdley, K.V.; Poordad, F.F.; Sheikh, A.M.; Afdhal, N.H.; Bernstein, D.E.; Dejesus, E.; Freilich, B., et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naïve patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. *Lancet Infect Dis* **2013**, 13, 401-408, doi:10.1016/S1473-3099(13)70033-1.
22. Lawitz, E.; Mangia, A.; Wyles, D.; Rodriguez-Torres, M.; Hassanein, T.; Gordon, S.C.; Schultz, M.; Davis, M.N.; Kayali, Z.; Reddy, K.R., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. *N Engl J Med* **2013**, 368, 1878-1887, doi:10.1056/NEJMoa1214853.
23. Sato, M.; Maekawa, S.; Komatsu, N.; Tatsumi, A.; Miura, M.; Muraoka, M.; Suzuki, Y.; Amemiya, F.; Takano, S.; Fukasawa, M., et al. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus. *J Virol* **2015**, 89, 6105-6116, doi:10.1128/JVI.03127-14.
24. Stross, C.; Shimakami, T.; Haselow, K.; Ahmad, M.Q.; Zeuzem, S.; Lange, C.M.; Welsch, C. Natural HCV variants with increased replicative fitness due to NS3 helicase mutations in the C-terminal helix alpha18. *Scientific reports* **2016**, 6, 19526, doi:10.1038/srep19526.
25. Sullivan, J.C.; De Meyer, S.; Bartels, D.J.; Dierynck, I.; Zhang, E.Z.; Spinks, J.; Tigges, A.M.; Ghys, A.; Dorrian, J.; Adda, N., et al. Evolution of treatment-emergent

- 686 resistant variants in telaprevir phase 3 clinical trials. *Clin Infect Dis* **2013**, 57, 221-229,
687 doi:10.1093/cid/cit226.
- 688 26. Svarovskaia, E.S.; Dvory-Sobol, H.; Parkin, N.; Hebner, C.; Gontcharova, V.; Martin,
689 R.; Ouyang, W.; Han, B.; Xu, S.; Ku, K., et al. Infrequent development of resistance in
690 genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3
691 clinical trials. *Clin Infect Dis* **2014**, 59, 1666-1674, doi:10.1093/cid/ciu697.
- 692 27. Gallego, I.; Sheldon, J.; Moreno, E.; Gregori, J.; Quer, J.; Esteban, J.I.; Rice, C.M.;
693 Domingo, E.; Perales, C. Barrier-Independent, Fitness-Associated Differences in
694 Sofosbuvir Efficacy against Hepatitis C Virus. *Antimicrobial agents and chemotherapy*
695 **2016**, 60, 3786-3793, doi:10.1128/AAC.00581-16.
- 696 28. Gallego, I.; Gregori, J.; Soria, M.E.; Garcia-Crespo, C.; Garcia-Alvarez, M.; Gomez-
697 Gonzalez, A.; Valiergue, R.; Gomez, J.; Esteban, J.I.; Quer, J., et al. Resistance of high
698 fitness hepatitis C virus to lethal mutagenesis. *Virology* **2018**, 523, 100-109,
699 doi:10.1016/j.virol.2018.07.030.
- 700 29. Sheldon, J.; Beach, N.M.; Moreno, E.; Gallego, I.; Pineiro, D.; Martinez-Salas, E.;
701 Gregori, J.; Quer, J.; Esteban, J.I.; Rice, C.M., et al. Increased replicative fitness can
702 lead to decreased drug sensitivity of hepatitis C virus. *J Virol* **2014**, 88, 12098-12111,
703 doi:10.1128/JVI.01860-14.
- 704 30. Donaldson, E.F.; Harrington, P.R.; O'Rear, J.J.; Naeger, L.K. Clinical evidence and
705 bioinformatics characterization of potential hepatitis C virus resistance pathways for
706 sofosbuvir. *Hepatology* **2015**, 61, 56-65, doi:10.1002/hep.27375.
- 707 31. Lontok, E.; Harrington, P.; Howe, A.; Kieffer, T.; Lennerstrand, J.; Lenz, O.; McPhee,
708 F.; Mo, H.; Parkin, N.; Pilot-Matias, T., et al. Hepatitis C virus drug resistance-
709 associated substitutions: State of the art summary. *Hepatology* **2015**, 62, 1623-1632,
710 doi:10.1002/hep.27934.
- 711 32. Sarrazin, C. The importance of resistance to direct antiviral drugs in HCV infection in
712 clinical practice. *J Hepatol* **2016**, 64, 486-504, doi:10.1016/j.jhep.2015.09.011.
- 713 33. Soria, M.E.; Gregori, J.; Chen, Q.; Garcia-Cehic, D.; Llorens, M.; de Avila, A.I.; Beach,
714 N.M.; Domingo, E.; Rodriguez-Frias, F.; Buti, M., et al. Pipeline for specific subtype
715 amplification and drug resistance detection in hepatitis C virus. *BMC Infect Dis* **2018**,
716 18, 446, doi:10.1186/s12879-018-3356-6.
- 717 34. Feng, D.F.; Doolittle, R.F. Progressive alignment of amino acid sequences and
718 construction of phylogenetic trees from them. *Methods in Enzymol.* **1996**, 266, 368-382.
- 719 35. García-Crespo, C.; Soria, M.E.; Gallego, I.; De Ávila, A.I.; Martínez-González, B.;
720 Vázquez-Sirvent, L.; Gómez, J.; Briones, C.; Gregori, J.; Quer, J., et al. Dissimilar
721 conservation pattern in hepatitis C virus mutant spectra, consensus sequences, and data
722 banks. **2020**, Submitted for publication.
- 723 36. Lambert, S.M.; Langley, D.R.; Garnett, J.A.; Angell, R.; Hedgethorpe, K.; Meanwell,
724 N.A.; Matthews, S.J. The crystal structure of NS5A domain 1 from genotype 1a reveals
725 new clues to the mechanism of action for dimeric HCV inhibitors. *Protein science : a*
726 *publication of the Protein Society* **2014**, 23, 723-734, doi:10.1002/pro.2456.
- 727 37. Uchida, Y.; Nakamura, S.; Kouyama, J.I.; Naiki, K.; Motoya, D.; Sugawara, K.; Inao,
728 M.; Imai, Y.; Nakayama, N.; Tomiya, T., et al. Significance of NS5B Substitutions in
729 Genotype 1b Hepatitis C Virus Evaluated by Bioinformatics Analysis. *Scientific reports*
730 **2018**, 8, 8818, doi:10.1038/s41598-018-27291-7.
- 731 38. Costa, V.D.; Brandao-Mello, C.E.; Nunes, E.P.; Dos Santos Silva, P.G.C.; de Souza
732 Rodrigues, L.; Lampe, E.; do Amaral Mello, F.C. Treatment of chronic HCV infection
733 with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in
734 NS5A and NS5B genes. *PLoS One* **2019**, 14, e0216327,
735 doi:10.1371/journal.pone.0216327.
- 736 39. Farci, P. New insights into the HCV quasispecies and compartmentalization. *Semin*
737 *Liver Dis* **2011**, 31, 356-374, doi:10.1055/s-0031-1297925.
- 738 40. Domingo, E.; Soria, M.E.; Gallego, I.; de Avila, A.I.; Garcia-Crespo, C.; Martinez-
739 Gonzalez, B.; Gomez, J.; Briones, C.; Gregori, J.; Quer, J., et al. A new implication of

- quasispecies dynamics: Broad virus diversification in absence of external perturbations. *Infect Genet Evol* **2020**, 82, 104278, doi:10.1016/j.meegid.2020.104278.
41. Mawatari, S.; Oda, K.; Tabu, K.; Ijuin, S.; Kumagai, K.; Fujisaki, K.; Hashiguchi, M.; Inada, Y.; Uto, H.; Hiramane, Y., et al. The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir. *PLoS One* **2018**, 13, e0198642, doi:10.1371/journal.pone.0198642.
42. Kim, D.W.; Lee, S.A.; Kim, H.; Won, Y.S.; Kim, B.J. Naturally occurring mutations in the nonstructural region 5B of hepatitis C virus (HCV) from treatment-naive Korean patients chronically infected with HCV genotype 1b. *PLoS One* **2014**, 9, e87773, doi:10.1371/journal.pone.0087773.
43. Bellocchi, M.C.; Aragri, M.; Carioti, L.; Fabeni, L.; Pipitone, R.M.; Brancaccio, G.; Sorbo, M.C.; Barbaliscia, S.; Di Maio, V.C.; Bronte, F., et al. NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients. *Cells* **2019**, 8, doi:10.3390/cells8070666.
44. Nakamoto, S.; Kanda, T.; Wu, S.; Shirasawa, H.; Yokosuka, O. Hepatitis C virus NS5A inhibitors and drug resistance mutations. *World J Gastroenterol* **2014**, 20, 2902-2912.
45. Asahina, Y.; Izumi, N.; Enomoto, N.; Uchihara, M.; Kurosaki, M.; Onuki, Y.; Nishimura, Y.; Ueda, K.; Tsuchiya, K.; Nakanishi, H., et al. Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. *J. Hepatol.* **2005**, 43, 623-629.
46. Hamano, K.; Sakamoto, N.; Enomoto, N.; Izumi, N.; Asahina, Y.; Kurosaki, M.; Ueda, E.; Tanabe, Y.; Maekawa, S.; Itakura, J., et al. Mutations in the NS5B region of the hepatitis C virus genome correlate with clinical outcomes of interferon-alpha plus ribavirin combination therapy. *J Gastroenterol Hepatol* **2005**, 20, 1401-1409, doi:10.1111/j.1440-1746.2005.04024.x.
47. Jiang, M.; Zhang, E.Z.; Ardzinski, A.; Tigges, A.; Davis, A.; Sullivan, J.C.; Nelson, M.; Spinks, J.; Dorrian, J.; Nicolas, O., et al. Genotypic and phenotypic analyses of hepatitis C virus variants observed in clinical studies of VX-222, a nonnucleoside NS5B polymerase inhibitor. *Antimicrobial agents and chemotherapy* **2014**, 58, 5456-5465, doi:10.1128/AAC.03052-14.
48. Ikram, A.; Zaheer, T.; Awan, F.M.; Obaid, A.; Naz, A.; Hanif, R.; Paracha, R.Z.; Ali, A.; Naveed, A.K.; Janjua, H.A. Exploring NS3/4A, NS5A and NS5B proteins to design conserved subunit multi-epitope vaccine against HCV utilizing immunoinformatics approaches. *Scientific reports* **2018**, 8, 16107, doi:10.1038/s41598-018-34254-5.
49. Domingo, E.; de Avila, A.I.; Gallego, I.; Sheldon, J.; Perales, C. Viral fitness: history and relevance for viral pathogenesis and antiviral interventions. *Pathogens and disease* **2019**, 77, doi:10.1093/femspd/ftz021.
50. Perales, C.; Beach, N.M.; Gallego, I.; Soria, M.E.; Quer, J.; Esteban, J.I.; Rice, C.; Domingo, E.; Sheldon, J. Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype. *J Virol* **2013**, 87, 7593-7607.
51. Farci, P.; Strazzera, R.; Alter, H.J.; Farci, S.; Degioannis, D.; Coiana, A.; Peddis, G.; Usai, F.; Serra, G.; Chessa, L., et al. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. *Proc Natl Acad Sci U S A* **2002**, 99, 3081-3086, doi:10.1073/pnas.052712599.
52. Gregori, J.; Salicru, M.; Domingo, E.; Sanchez, A.; Esteban, J.I.; Rodriguez-Frias, F.; Quer, J. Inference with viral quasispecies diversity indices: clonal and NGS approaches. *Bioinformatics* **2014**, 30:1104-1111, doi:10.1093/bioinformatics/btt768, doi:10.1093/bioinformatics/btt768.

Figure 1

Figure 1 (*continued*)

Figure 3

A

B

Figure 4

Figure 6

A

B

Figure 7